Summaries of Errant Gene Therapeutics vs. Sloan Kettering Court Exhibits

Summaries of Errant Gene Therapeutics vs. Sloan Kettering Court Exhibits

On August 19, 2019, Errant Gene Therapeutics met the face of victory when “the New York Supreme Court Justice Barry Ostrager sanctioned Bluebird Bio, Inc. (“Bluebird”) and rejected Bluebird’s efforts to prevent EGT from proceeding with its lawsuit in Massachusetts against Bluebird CEO Nick Leschly and Bluebird’s venture capital partner, Third Rock Ventures, LLC (“TRV”),” as reported by Business Wire.

In addition to this major win, Judge Ostrager made all court materials public, which can be found here. TrialSite News has also summarized the most telling exhibits below.

Exhibit 14 covers the details of the contract between bluebird bio. (BBB) and Sloan-Kettering Institute (SKI), which was entered into on Nov 21, 2011. This exhibit also entails miscellaneous information, such as Research Plans, Vector Designs, Summary of Personnel Costs, Licensed Patents and more.
Exhibit 15 showcases Nick Leschly’s “Shut Down Pat” email, sent June 18, 2010, in which he states: “Pat Girondi – need to shut him down…curious what he called about…my emails were clear want to get him to buy into a CDA to review Michel’s data. Be nice, suck up, etc… if you think (and I think) that Michel has val...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee